BackBellerophon Therapeutics Overview

Bellerophon Therapeutics Net Income

Latest net income for BLPH: $-12M, below the Healthcare sector average of $16B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$1.92M
61.75% YoY

As of Sep 2023

Annual Net Income (TTM)

-$11.67M
38.7% YoY

Trailing 12 months ending Sep 2023

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Bellerophon Therapeutics (BLPH) FAQ

Bellerophon Therapeutics (BLPH) currently reports a net income of $-12M as of September 2023. That compares with $-19M in the prior-year period — up 38.7% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Bellerophon Therapeutics's net income history and peer comparisons.

Bellerophon Therapeutics's net income increased from $-19M to $-12M — a 38.7% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bellerophon Therapeutics's net income of $-12M is lower than the Healthcare sector average of $16B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Bellerophon Therapeutics reported $-12M in net income as of September 2023. That compares with $-19M in the prior-year period — up 38.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-12M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Bellerophon Therapeutics, and consider following BLPH for alerts when major investors trade the stock.